Grifols today announced that the European Commission has approved U.S.-based Rigel Pharmaceuticals' TAVLESSE® (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. The launch of TAVLESSE® in Europe and Turkey, where Grifols has exclusive rights, reinforces Grifols’ commercial strategy and reflects the company’s commitment to continue expanding its product portfolio to benefit patients. For more information:
2019 has been a year of great achievements for Grifols. As we turned 110 years old, we launched new solutions to provide better treatment options for our patients, presented promising AMBAR results that show the potential of plasma proteins to treat high-prevalence diseases, and once again received recognition for the industrial excellence of our state-of-the-art facilities.
We begin another year as committed as ever to our mission: continuing to help thousands of people around the world. Our horizons keep expanding with our pioneering spirit leading the way.
Our best wishes for the New Year!
Grifols today reinforced its leadership in treating diseases with immunoglobulins (IG) as it launched Xembify®, the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients with primary immunodeficiency (PI). With Xembify, the company continues to expand its industry-leading portfolio of plasma-derived medicines to enhance the health and well-being of patients around the world.
Grifols today at the CTAD conference in San Diego released new and complete data from its breakthrough clinical trial on Alzheimer’s disease, AMBAR, strengthening previous results that show a reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s. New neuroimaging data show less neuronal damage in patients receiving the plasma proteins albumin and immunoglobulin, the mainstays of the AMBAR protocol. Grifols also announced another clinical trial in 2020, AMBAR II, to complement the just-completed study.
Grifols expands in Latin America with the start of production of its new blood-collection systems plant in Campo Largo, Brazil. With an annual capacity in excess of 10 million blood collection bags, the more than 5,500-square-meter plant is expected to gradually increase output to serve the broader Latin American region.
Grifols continued to deliver strong financial results in 2019, reporting 3.7 billion in revenues for the first nine months of the year. The company delivered solid performance across all its business divisions. Please see full results here: http://glassdoor.com/slink.htm?key=vMHXw
Grifols is proud to celebrate International Plasma Awareness Week. We appreciate the kindness and generosity of plasma donors everywhere for helping to save patients’ lives. To learn more about the importance of plasma donation, visit http://glassdoor.com/slink.htm?key=vMRg8
There are nearly 50 million people living with dementia worldwide. Two out of every three cases are caused by Alzheimer's disease, which, despite significant research and investment, remains incurable. Awareness and understanding are necessary to end with the misconceptions that surround Alzheimer’s. Let's all continue working to defeat this disease. #WorldAlzheimersDay #alzheimersawareness #alzheimersdisease #GrifolsAMBAR
Grifols continues to deliver strong financial performance, reporting revenue growth of 14.3% to 2.4 billion euros in the first half of 2019.
Grifols continues to release positive data that reinforce the efficacy of AMBAR, the company’s breakthrough clinical study to treat Alzheimer’s Disease.